XBIT News and Press, XBiotech Inc. From 09/21/20

AUSTIN, Texas, Sept. 21, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined infections with influenza and COVID-19. With the global spread of the novel CO...

"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," says the NIH . "There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for th...

The chief of the FDA is willing to bypass the full federal approval process in order to make a COVID-19 vaccine available as soon as possible. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news Read more ...

Investors in convalescent plasma players have experienced a bit of volatility of late related to the FDA emergency use nod to treat COVID-19 patients. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news, Read more ...

XBiotech (NASDAQ: XBIT ) announces that FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, thus opening door for the company’s antibody screening technology. More news on: XBiotech Inc., Stocks on the move, Read more ...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +67%  on FDA nod for convalescent plasma. More news on: Sonnet BioTherapeutics Holdings, Inc., Liminal BioSciences Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients Under Collaboration BioBridge Global Will Be Using XBiotech’s COVID-19 Antibody Test to Identify the Convalescent Blood Products AUSTIN, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- XBiotech...

"On the therapeutics front...in our battle against the China virus that will save countless lives, the FDA has issued an emergency use authorization — and that's such powerful term, emergency use authorization — for a treatment known as convalescent plasma," President Trump s...

Processors of antibody-rich convalescent plasma, derived from COVID-19 patients who have recovered from the infection, are under the gun on a delay of the expected emergency use authorization from the FDA for the treatment of COVID-19. More news on: Kamada Ltd., Grifols, S.A., XBiotech I...

Sanofi agrees to acquire Principia Bio for $3.68 billion Sanofi ( SNY ) announced that it has agree to buy Principia Biopharma Inc. ( PRNB ) for $3.68 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. Sanofi believes that the acquisition...